Shift from Cotesting to HPV Primary Test: How much We are Prepared and What We Need to Do
Need to claim your poster? Find the KiKo table at the conference and they'll help
you get set up.
Presented at: American Society of Cytopathology 2024
Date: 2024-11-08 00:00:00
Views: 8
Summary: Introduction: The greater understanding of persistent high-risk human papillomavirus (hrHPV) infection as a major cause of cervical cancer has led to new recommendations for screening strategies. Worldwide, there has been a gradual shift toward using hrHPV PCR as a primary screening tool. While HPV testing alone at longer intervals has shown great detection rates, we highlight the risk of missing high-grade dysplasia based on negative hrHPV test results.
Materials and Methods: 24,412 PAP smears (ThinPrep) were collected at a county hospital during a 48-month period (2019-2023), and 38,157 smears at a private clinic during 28-month period (2020-2023). Patients with HSIL on PAP smear were investigated for corresponding hrHPV infection and surgical biopsies. Only patients with valid cotesting (hrHPV test and cytology) and biopsy-proven CIN 2 or worse lesions were included. In both populations, the Aptima HPV Assay, based on m-RNA detection, was used to evaluate for hrHPV.
Results: At the county hospital, 155 patients had HSIL on cytology and 114 patients were included. 2 of 114 (1.8%) patients had persistent negative hrHPV tests. Two patients had one positive hrHPV among multiple tests within 3 years. At the private clinic, 87 patients had HSIL on cytology and 48 patients were included. 2 of 48 patients (4.1 %) had persistent negative hrHPV tests. The average age of the patients with negative hrHPV tests was 60 and 36 years, respectively.
Conclusions: Our study demonstrated that a small percentage (1.8-4.1%) of patients with HSIL, detected by co-testing, was missed by hrHPV test alone. The detection rate of hrHPV as a screening test can vary based on the demographics of the population, collection method, low viral load, limited targeted viral probes, and DNA or m-RNA detection-based methodology. Guidelines for re-testing hrHPV, follow-up of cases with negative hrHPV in different risk groups, and cytology's future role are necessary to establish.